Bellus Health

📍 Laval, Canada👥 81 employees💰 Last funded 2021
Biotechnology Research🌐 gsk.com
Website LinkedIn
BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of chronic cough and chronic pruritus. P2X3 receptors are channels expressed in sensory nerves throughout the body and play an important role in the sensitization of the nervous system to various stimuli. BELLUS is exploring how P2X3 activation contributes to irritation and pain, and whether inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders. BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on both Nasdaq and the Toronto Stock Exchange.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Bellus Health?
Bellus Health has 1 investors on record on gritt.io.
When did Bellus Health last raise funding?
The most recent investment in Bellus Health recorded on gritt.io was in 2021.
What industry is Bellus Health in?
Bellus Health operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Bellus Health based?
Bellus Health is headquartered in Laval, Canada.